Affordable Access

Access to the full text

Botulinum toxin type A for painful diabetic neuropathy: an open-label study

Authors
  • Helmy, Shahinaz1
  • Emara, Tamer1
  • Menem, Amr Abdel1
  • 1 Ain Shams University, Cairo, Egypt , Cairo (Egypt)
Type
Published Article
Journal
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Publisher
Springer Berlin Heidelberg
Publication Date
May 17, 2021
Volume
57
Issue
1
Identifiers
DOI: 10.1186/s41983-021-00315-2
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundA large proportion of painful diabetic neuropathy cases either do not respond or are intolerant to the currently available oral and physical therapies. There is encouraging evidence from a small number of studies that those patients can improve using botulinum toxin injection. The aim of the study was to evaluate the effect of intradermal injection of botulinum toxin type A on painful diabetic neuropathy. Eight adult patients with diabetic peripheral neuropathy (DPN), confirmed by nerve conduction studies, were refractory to a minimum of two neuropathic pain treatments for 6 months or more were recruited. All cases received intradermal injection of 48 units of botulinum toxins—type A in each foot in 6×4 distribution. Follow-up was done after 8 weeks using the Neuropathic Pain Scale (NPS), Pittsburgh Sleep Quality Index (PSQI), and Overall Disability Sum Scale (ODSS).ResultsAfter 8 weeks, there was a significant change in NPS from 55.8 (7.8) to 38.5 (8.1) (p value 0.007), also there was significant improvement in ODDS from 4 (IQR, 2.25-4.75) to 2.5 (IQR, 0.5-3) (p value 0.01). However, there was no significant change in PSQI.ConclusionBotulinum toxin type A injection is a promising treatment option in Egyptian DPN adults in this study.

Report this publication

Statistics

Seen <100 times